Actionable news
All posts from Actionable news
Actionable news in OCUL: OCULAR THERAPEUTIX Inc,

Why Ocular Therapeutix (OCUL) Stock Is Tanking Today

NEW YORK (TheStreet) -- Shares of Ocular Therapeutix (OCUL) are plunging 43.46% to $6.70 on heavy trading volume early Monday afternoon after a second Phase 3 trial of its pink eye treatment, Dextenza, didn't achieve its single primary endpoint.

The endpoint was defined as the difference in the mean scores in ocular itching between the treatment group and placebo group at three different time points seven days after the insertion of the depots.

"We are disappointed that the primary endpoint of ocular itching associated with allergic conjunctivitis was not achieved...